AK
Akebia Therapeutics, Inc.
AKBA · NASDAQ
$0.97 -1.35% (-$0.01)
1M +15.49%
Market Cap $263.8M
P/E Ratio -
Div. Yield -
ROE 93.74%
Bulios Fair Price
$1.33
36.5% upside
Current Price
$0.97
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AKBA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
78 /100
Cheap P/S 1.20x
P/B 10.54x
P/FCF 6.56x
Growth
22 /100
Declining Rev. growth 6.88%
Book val. growth 84.06%
EPS growth N/A
Profitability
50 /100
Moderate Gross margin 79.48%
Net margin 13.54%
Op. margin 6.91%
Quality
8 /100
Poor ROIC 7.54%
ROE 93.74%
ROA 8.48%
Debt
22 /100
High Debt/Equity 2.16x
Current ratio 1.43x
Int. coverage -2.50x
Stability
12 /100
Unstable Beta 0.24x
Rev. volatility 42.90%
EPS volatility 56.34%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AKBA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Butler
Employees
194
Headquarters
Cambridge
Upcoming events
09 NOV
Earnings
Upcoming earnings report